Systematic Review of Efficacy and Safety of Avacopan in Real-World Clinical Practice

Introduction: Avacopan, a complement 5a receptor (C5aR) antagonist, is a therapeutic option for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and is used as a steroid-sparing agent. The efficacy and safety of avacopan were established in the pivotal phase III...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ilay Berke, Felix Keller, Clemens Untersulzner, Jae Il Shin, Peong Gang Park, Sarah Soyeon Oh, Jasper Callemeyn, Andreas Kronbichler
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2026-04-01
Series:	Kidney International Reports
Assuntos:	ANCA avacopan complement treatment vasculitis
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S2468024925007715
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!